Royal Bank of Canada
DTIL icon

Royal Bank of Canada’s Precision BioSciences DTIL Stock Holding History

Royal Bank of Canada’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
97
-430
-82% -$1.98K ﹤0.01% 6855
2025
Q4 		$2K Buy
527
+526
+52,600% +$2.99K ﹤0.01% 6894
2025
Q3 		$0 Sell
1
-41,982
-100% -$201K ﹤0.01% 7207
2025
Q2 		$176K Buy
41,983
+1,983
+5% +$9.78K ﹤0.01% 5251
2025
Q1 		$191K Sell
40,000
-2,303
-5% -$11.7K ﹤0.01% 4733
2024
Q4 		$161K Buy
42,303
+9,079
+27% +$66.3K ﹤0.01% 4992
2024
Q3 		$298K Buy
+33,224
New +$320K ﹤0.01% 4511
2024
Q2 		– Sell
-9
Closed – – 7158
2024
Q1 		$0 Buy
9
+4
+80% +$49 ﹤0.01% 7134
2023
Q4 		$0 Sell
5
-6
-55% -$65 ﹤0.01% 7223
2023
Q3 		$0 Sell
11
-84
-88% -$1.29K ﹤0.01% 7183
2023
Q2 		$2K Buy
95
+36
+61% +$823 ﹤0.01% 6859
2023
Q1 		$2K Buy
59
+52
+743% +$1.71K ﹤0.01% 6762
2022
Q4 		$0 Sell
7
-41
-85% -$1.62K ﹤0.01% 7325
2022
Q3 		$2K Buy
48
+43
+860% +$2.04K ﹤0.01% 7005
2022
Q2 		$0 Sell
5
-1,675
-100% -$98.3K ﹤0.01% 7445
2022
Q1 		$155K Sell
1,680
-827
-33% -$112K ﹤0.01% 5309
2021
Q4 		$557K Buy
2,507
+384
+18% +$107K ﹤0.01% 4350
2021
Q3 		$735K Sell
2,123
-204
-9% -$69.1K ﹤0.01% 3992
2021
Q2 		$874K Sell
2,327
-136
-6% -$40.8K ﹤0.01% 3776
2021
Q1 		$765K Buy
2,463
+18
+0.7% +$6.3K ﹤0.01% 3824
2020
Q4 		$612K Buy
2,445
+844
+53% +$207K ﹤0.01% 3962
2020
Q3 		$296K Buy
1,601
+595
+59% +$118K ﹤0.01% 4253
2020
Q2 		$251K Sell
1,006
-474
-32% -$104K ﹤0.01% 4288
2020
Q1 		$268K Buy
1,480
+56
+4% +$14.7K ﹤0.01% 4117
2019
Q4 		$593K Buy
1,424
+1,327
+1,368% +$417K ﹤0.01% 3855
2019
Q3 		$24K Hold
97
– – ﹤0.01% 5416
2019
Q2 		$38K Buy
+97
New +$39.1K ﹤0.01% 5412

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada's DTIL Position: Q1 2026 in Review

Royal Bank of Canada reduced its Precision BioSciences (DTIL) stake by 82% in Q1 2026, selling an estimated $1.98K and leaving 97 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6855.

Royal Bank of Canada first reported a position in DTIL in Q2 2019 and has held it in 27 quarters since. The position peaked at $874K in Q2 2021. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Royal Bank of Canada held 97 shares of Precision BioSciences worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 430 Precision BioSciences shares in Q1 2026, an estimated $1.98K.
  • Precision BioSciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6855 holding.
  • Royal Bank of Canada first reported a position in Precision BioSciences in Q2 2019 and has held it in 27 quarters since.
  • Royal Bank of Canada's Precision BioSciences position peaked at $874K in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.